Need of education on biosimilars amongst ophthalmologists: combating the nocebo effect
Open Access
- 29 November 2019
- journal article
- editorial
- Published by Springer Nature in Eye
- Vol. 34 (6) , 1006-1007
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular DegenerationOphthalmology, 2020
- Abicipar pegol: the non-monoclonal antibody anti-VEGFEye, 2019
- Brolucizumab: is extended VEGF suppression on the horizon?Eye, 2019
- Ophthalmic biosimilars: Lessons from IndiaIndian Journal Of Ophthalmology, 2019
- Understanding biosimilars and its regulatory aspects across the globe: an ophthalmology perspectiveBritish Journal of Ophthalmology, 2019
- Biosimilars in ophthalmology: “Is there a big change on the horizon?”Clinical Ophthalmology, 2018
- Identification of multiple serine to asparagine sequence variation sites in an intended copy product of LUCENTIS® by mass spectrometrymAbs, 2017
- Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti–vascular endothelial growth factor therapy of macular diseasesGraefe's Archive for Clinical and Experimental Ophthalmology, 2017